Corcept TherapeuticsvsJohnson & Johnson

CORT and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CORT

Corcept Therapeutics Incorporated

$70.07

Value $7.5B

+1.23%
CORT's page

Corcept Therapeutics (CORT) has a market value of $7.5B and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, CORT moved -7.2% and JNJ +45.4%. The P/E is 46.8 for CORT and 41.7 for JNJ. Dividend yield: CORT none, JNJ 1.89%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CORT$7.5B

    JNJ$672B

    JNJ is 90 times CORT

  • Revenue, 12 months

    CORT$964M

    JNJ$99.3B

    JNJ is 103 times CORT

  • Net income, 12 months

    CORT$162M

    JNJ$16.1B

    JNJ is 99 times CORT

  • Operating margin

    CORT11.5%

    JNJ–

  • ROIC

    CORT12.7%

    JNJ12.4%

    0.3 points apart

  • P/E

    CORT46.8

    JNJ41.7

    CORT is 1.1 times JNJ

  • Dividend yield

    CORT0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    CORT+200.7%

    JNJ+97.0%

    103.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CORT+200.7%

JNJ+97.0%

20040020222023202420252026
Returns by period
PeriodCORTWith dividendsJNJWith dividends
1 year since November 14, 2025-7.2%Price -7.2%+45.4%Price +42.2%
3 years since November 17, 2023+170.4%+39.3% a yearPrice +170.4%+102.6%+26.5% a yearPrice +86.1%
5 years since November 16, 2021+200.7%+24.6% a yearPrice +200.7%+97.0%+14.5% a yearPrice +71.3%
10 years since November 18, 2016+641.5%+22.2% a yearPrice +641.5%+214.8%+12.2% a yearPrice +141.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CORTCorcept TherapeuticsJNJJohnson & Johnson

Valuation

CORTJNJ
Valuation
Price$70.07$278.70
Market value$7.5B$672B
Enterprise value (EV)$7.1B$699B
P/E46.841.7
P/E, 5-year median34.621.9
P/B8.98.2
EV/EBIT63.939.4
Free cash flow yield2.6%3.1%

Results and growth

CORTJNJ
Results and growth
Revenue, 12 months$964M$99.3B
Net income, 12 months$162M$16.1B
Free cash flow, 12 months$195M$20.6B
Earnings per share, 12 months$1.50$6.59
Revenue growth, year on year12.8%6.1%
Revenue growth a year, past+16.6%over 5 years+2.7%over 5 years
EPS growth a year, past-0.7%over 5 years+14.9%over 5 years

Margins and returns on capital

CORTJNJ
Margins and returns on capital
Gross margin98.5%67.6%
Operating margin11.5%–
Net margin16.8%16.2%
ROIC12.7%12.4%
ROE23.5%19.7%

Balance sheet

CORTJNJ
Balance sheet
Cash$371M$17.2B
Total debt$9.0M$44.7B
Net debt / EBITDA-3.31.1
Interest cover–18.0×

Dividends and buybacks

CORTJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield2.3%0.9%
Shareholder yield2.3%2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CORT or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Corcept Therapeutics or Johnson & Johnson?

By market value, Johnson & Johnson ($672B) is about 90.1 times Corcept Therapeutics ($7.5B), at today's prices.

How did CORT and JNJ stock do over the last 10 years?

Since November 18, 2016, CORT's price moved +641.5% and JNJ's +141.6%. With dividends: CORT +641.5% (+22.2% a year), JNJ +214.8% (+12.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, CORT or JNJ?

The dividend yield at today's price is none for Corcept Therapeutics and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of CORT and JNJ?

At today's price, the P/E is 46.8 for CORT and 41.7 for JNJ. The median of the last five years was 34.6 and 21.9, which shows where each stands against its own past.

Which has the higher profit margins, Corcept Therapeutics or Johnson & Johnson?

Over the last twelve months, the net margin was 16.8% for Corcept Therapeutics and 16.2% for Johnson & Johnson, and the operating margin 11.5% and –. Revenue was $964M and $99.3B.

Which is the better investment, Corcept Therapeutics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.